Survey and research of usefulness and issue on the PDX models for the anti-cancer drug development
The developments of anti-cancer drugs are involved in cancer cell lines derived from cancer patients and CDX models in which these cells are transplanted into immunodeficient mice. However, there are many cases that the results of preclinical studies do not match to that of clinical studies, because the characteristics of the cells passaged many times are different from that of the original cells. Since the interaction between cancer cells and cancer-associated stromal cells is influenced to the drug response, the importance of the PDX model that reproduces cancer microenvironment is increasing. Therefore, the aim of this study is to clarify usefulness and issue on the PDX model for the drug development.
PDX models and ex vivo models for drug development
PDX models with various omics information have been established and are used for preclinical and clinical research. On the other hand, 3D culture models such as patient-derived cells and organoids are recognized as models similar to the patient. In this study, we will standardize methods for establishing cell lines, organoids, and PDX models from patient-derived samples under the quality control and establish a system for co-clinical trial that directly compares the results of preclinical and clinical research.